These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24856168)

  • 1. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
    Alipour M; Suntres ZE
    Ther Deliv; 2014 Apr; 5(4):409-27. PubMed ID: 24856168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
    Antonela Antoniu S
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
    Azoicai D; Antoniu SA
    Expert Opin Investig Drugs; 2013 Feb; 22(2):267-76. PubMed ID: 23176385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
    Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
    Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
    Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
    Taccetti G; Campana S; Festini F; Mascherini M; Döring G
    Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.
    Alhariri M; Omri A
    Antimicrob Agents Chemother; 2013 Jan; 57(1):569-78. PubMed ID: 23147741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa.
    Hadinoto K; Cheow WS
    Colloids Surf B Biointerfaces; 2014 Apr; 116():772-85. PubMed ID: 24656614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
    Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO
    Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection.
    Boukerb AM; Rousset A; Galanos N; Méar JB; Thépaut M; Grandjean T; Gillon E; Cecioni S; Abderrahmen C; Faure K; Redelberger D; Kipnis E; Dessein R; Havet S; Darblade B; Matthews SE; de Bentzmann S; Guéry B; Cournoyer B; Imberty A; Vidal S
    J Med Chem; 2014 Dec; 57(24):10275-89. PubMed ID: 25419855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
    Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
    J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats.
    Marier JF; Brazier JL; Lavigne J; Ducharme MP
    J Antimicrob Chemother; 2003 Aug; 52(2):247-52. PubMed ID: 12837733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.